Agata A. Bielska
Agata A. Bielska has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Craig B. Thompson
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, USA
22 shared publications - Caitlin F. Harrigan
Department of Computer Science, University of Toronto, Toronto, Canada
21 shared publications Quaid Morris
21 shared publications- Wilhelm Palm
Division of Cell Signaling and Metabolism, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany
21 shared publications - Yeon Ju Kyung
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York
21 shared publications - Rakesh Kumar
Oncology R&D, AstraZeneca, Gaithersburg, Maryland
16 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 31 May 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (8) , 1-9
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
In the phase II NeoCOAST-2 platform study, 202 patients with untreated, resectable stage IIA–IIIB non-small-cell lung cancer (NSCLC) were randomized to receive neoadjuvant durvalumab plus platinum-doublet chemotherapy with oleclumab, a CD73 inhibitor (Arm 1), or with monalizumab, a NKG2A inhibitor (Arm 2), or neoadjuvant durvalumab plus single-agent platinum chemotherapy with the TROP-2 antibody–drug conjugate (ADC) datopotamab deruxtecan (Arm 4), followed by surgical resection and adjuvant durvalumab with oleclumab or monalizumab (Arms 1 and 2) or durvalumab alone (Arm 4). Primary endpoints were pathological complete response (pCR) rate and safety; secondary endpoints included feasibility of surgery and major pathological response (mPR) rate. In the modified intention-to-treat population (n = 198; Arm 1, n = 74; Arm 2, n = 70; Arm 4, n = 54), pCR rates were 20.3% (15/74; 95% CI, 11.8–31.2), 25.7% (18/70; 95% CI, 16.0–37.6) and 35.2% (19/54; 95% CI, 22.7–49.4), and mPR rates were 41.9% (31/74; 95% CI, 30.5–53.9), 50.0% (35/70; 95% CI, 37.8–62.2) and 63.0% (34/54; 95% CI, 48.7–75.7) in arms 1, 2, and 4, respectively. In the safety population, 69/74 (93.2%), 66/71 (93.0%), and 51/54 (94.4%) patients underwent surgery, respectively. Overall, grade ≥3 treatment-related adverse events occurred in 27/74 (36.5%), 29/71 (40.8%) and 11/54 (20.4%) patients, respectively. In NeoCOAST-2, the first neoadjuvant trial examining an ADC plus chemo-immunotherapy in resectable NSCLC, pCR rates were highest in the datopotamab-deruxtecan-containing arm, warranting further investigation in larger trials of ADCs and checkpoint inhibition in the neoadjuvant setting. ClinicalTrials.gov identifier: NCT05061550.
- 31 May 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (8) , 1-9
Top Cited PapersOpen AccessPerioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
In the phase II NeoCOAST-2 platform study, 202 patients with untreated, resectable stage IIA–IIIB non-small-cell lung cancer (NSCLC) were randomized to receive neoadjuvant durvalumab plus platinum-doublet chemotherapy with oleclumab, a CD73 inhibitor (Arm 1), or with monalizumab, a NKG2A inhibitor (Arm 2), or neoadjuvant durvalumab plus single-agent platinum chemotherapy with the TROP-2 antibody–drug conjugate (ADC) datopotamab deruxtecan (Arm 4), followed by surgical resection and adjuvant durvalumab with oleclumab or monalizumab (Arms 1 and 2) or durvalumab alone (Arm 4). Primary endpoints were pathological complete response (pCR) rate and safety; secondary endpoints included feasibility of surgery and major pathological response (mPR) rate. In the modified intention-to-treat population (n = 198; Arm 1, n = 74; Arm 2, n = 70; Arm 4, n = 54), pCR rates were 20.3% (15/74; 95% CI, 11.8–31.2), 25.7% (18/70; 95% CI, 16.0–37.6) and 35.2% (19/54; 95% CI, 22.7–49.4), and mPR rates were 41.9% (31/74; 95% CI, 30.5–53.9), 50.0% (35/70; 95% CI, 37.8–62.2) and 63.0% (34/54; 95% CI, 48.7–75.7) in arms 1, 2, and 4, respectively. In the safety population, 69/74 (93.2%), 66/71 (93.0%), and 51/54 (94.4%) patients underwent surgery, respectively. Overall, grade ≥3 treatment-related adverse events occurred in 27/74 (36.5%), 29/71 (40.8%) and 11/54 (20.4%) patients, respectively. In NeoCOAST-2, the first neoadjuvant trial examining an ADC plus chemo-immunotherapy in resectable NSCLC, pCR rates were highest in the datopotamab-deruxtecan-containing arm, warranting further investigation in larger trials of ADCs and checkpoint inhibition in the neoadjuvant setting. ClinicalTrials.gov identifier: NCT05061550.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Exploratory overall survival analysis of oleclumab + durvalumab + GnP (Arm A3) versus GnP alone (Arm A1) by IHC or ctDNA-based biomarkers per all patients (A) or CD73 high only population (B)
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Exploratory overall survival analysis of oleclumab + durvalumab + GnP (Arm A3) versus GnP alone (Arm A1) by IHC or ctDNA-based biomarkers per all patients (A) or CD73 high only population (B)
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Table 3 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Efficacy in the dose-expansion phase (intent-to-treat population; N = 170).
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Efficacy in the dose-expansion phase (intent-to-treat population; N = 170).
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
A, PFS and (B) OS in the dose-expansion phase overall (ITT) population; (C) PFS and (D) OS in patients with low CD73 levels, and (E) PFS and (F) OS in patients with high CD73 levels. ITT, intent-to-treat; NC, not calculable.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
A, PFS and (B) OS in the dose-expansion phase overall (ITT) population; (C) PFS and (D) OS in patients with low CD73 levels, and (E) PFS and (F) OS in patients with high CD73 levels. ITT, intent-to-treat; NC, not calculable.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Figure 1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
CONSORT diagram for the dose-expansion phase. “a” denotes arm A1: death (n = 1); withdrawal by patient (n = 8); other (n = 4). Arm A3: death (n = 1); withdrawal by patient (n = 2); other (n = 2). “b” denotes patients could be counted more than once in this category if they discontinued different chemotherapy options for different reasons. “c” denotes as permitted per study protocol, patients from arms A2 and A3 continued to receive immunotherapy off-study after the study closure on July 22, 2022, and patients from all arms continued to receive treatment per standard of care at their site. “d” denotes end of study status as defined in the protocol. “e” denotes “sponsor decision" and includes patients either still on treatment or in survival follow-up at the time of study closure. N, number of patients in each treatment group.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
CONSORT diagram for the dose-expansion phase. “a” denotes arm A1: death (n = 1); withdrawal by patient (n = 8); other (n = 4). Arm A3: death (n = 1); withdrawal by patient (n = 2); other (n = 2). “b” denotes patients could be counted more than once in this category if they discontinued different chemotherapy options for different reasons. “c” denotes as permitted per study protocol, patients from arms A2 and A3 continued to receive immunotherapy off-study after the study closure on July 22, 2022, and patients from all arms continued to receive treatment per standard of care at their site. “d” denotes end of study status as defined in the protocol. “e” denotes “sponsor decision" and includes patients either still on treatment or in survival follow-up at the time of study closure. N, number of patients in each treatment group.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Study design: dose-escalation and dose-expansion phases
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Study design: dose-escalation and dose-expansion phases
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Baseline median variant allelic frequency (VAF) by KRAS status (A), exploratory OS and PFS stratified by baseline median VAF (B) and distribution of KRAS mutation status (C), VAF (D) and blood TMB (E) by arm
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Baseline median variant allelic frequency (VAF) by KRAS status (A), exploratory OS and PFS stratified by baseline median VAF (B) and distribution of KRAS mutation status (C), VAF (D) and blood TMB (E) by arm
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Patient demographics and disease characteristics in the dose-expansion phase (intent-to-treat population; N = 170).
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Patient demographics and disease characteristics in the dose-expansion phase (intent-to-treat population; N = 170).